Remdesivir and SARS-CoV-2 monoclonal antibodies to prevent COVID-19 progression in hematological patients: an observational study.

Juan Vicente-ValorCarmen Rodríguez-GonzálezMaría Ferris-VillanuevaEsther Chamorro-de-VegaRosa Romero-JiménezDaniel Gómez-CostasSergio Herrero-BermejoFrancisco Tejerina-PicadoSantiago Osorio-PrendesGillen Oarbeascoa-RoyuelaAna Herranz-AlonsoMaría Sanjurjo-Sáez

Published in: Pharmacological reports : PR (2023)

Our results from clinical practice suggest that RDV and SARS-CoV-2 mAb therapies elicit worse outcomes in hematological patients than those reported for high-risk population in clinical trials.

Keyphrases

sars cov
end stage renal disease
clinical trial
ejection fraction
chronic kidney disease
newly diagnosed
clinical practice
peritoneal dialysis
prognostic factors
coronavirus disease
respiratory syndrome coronavirus
type diabetes
metabolic syndrome
adipose tissue
skeletal muscle